ZW-251 shows optimal balance between safety and breadth of antitumor activity in models of HCC

Oct. 29, 2024

Researchers from Zymeworks Inc. presented preclinical data for the novel glypican-3 (GPC3)-targeting antibody-drug conjugate (ADC), ZW-251, being developed as an anticancer agent.

BioWorld Science Conferences AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Cancer Antibody-drug conjugate

Today's news in brief

BioWorld

BioWorld briefs for April 21, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 21, 2025.

Makary’s vision for slimmed-down US FDA somewhat reassuring

BioWorld

Nearly three weeks into the job, U.S. FDA Commissioner Marty Makary provided a comprehensive overview of his vision for the much-reduced agency, even as he’s...

Ouch! Tariffs hit med tech harder than expected

BioWorld MedTech

First quarter earnings reports from Johnson & Johnson and Abbott Laboratories provided some surprising insights into the likely hit med-tech companies will...

ADPD 2025: Novel treatment modalities in neurodegenerative disorders

BioWorld Science

The current treatment strategies for neurodegenerative diseases focus on targeting Aβ in Alzheimer’s disease (AD), α-synuclein aggregates in Parkinson’s disease...